

Table SIII. Clinical characteristics of The Cancer Genome Atlas-lung adenocarcinoma cohort.

Characteristic	Total (n=515)	Training (n=360)	Test (n=155)	P-value
Age, years; median (IQR)	65 (57-72)	64 (57-71)	66 (58-73)	0.15
Sex, n (%)				0.87
Male	243 (47.2)	171 (47.5)	72 (46.5)	
Female	272 (52.8)	189 (52.5)	83 (53.5)	
AJCC Stage, n (%)				0.92
I	268 (52.0)	188 (52.2)	80 (51.6)	
II	122 (23.7)	85 (23.6)	37 (23.9)	
III	86 (16.7)	60 (16.7)	26 (16.8)	
IV	39 (7.6)	27 (7.5)	12 (7.7)	
T Stage, n (%)				0.68
T1	173 (33.6)	123 (34.2)	50 (32.3)	
T2	272 (52.8)	187 (51.9)	85 (54.8)	
T3	49 (9.5)	36 (10.0)	13 (8.4)	
T4	21 (4.1)	14 (3.9)	7 (4.5)	
Treatment, n (%)				
Surgery only	184 (35.7)	130 (36.1)	54 (34.8)	0.79
Surgery + chemotherapy	302 (58.6)	210 (58.3)	92 (59.4)	
Radiation	108 (21.0)	76 (21.1)	32 (20.6)	0.91
Targeted therapy	64 (12.4)	44 (12.2)	20 (12.9)	0.83
Immunotherapy	15 (2.9)	11 (3.1)	4 (2.6)	0.76
Survival status, n (%)				0.94
Alive	319 (61.9)	223 (61.9)	96 (61.9)	
Dead	196 (38.1)	137 (38.1)	59 (38.1)	
Follow-up, months; median (IQR)	32.6 (15-54)	33.1 (15-55)	31.8 (14-52)	0.41

Wilcoxon test; Chi-square test. IQR, interquartile range.